Binding of 3,4,5,6-Tetrahydroxyazepanes to the Acid-β-glucosidase Active Site: Implications for Pharmacological Chaperone Design for Gaucher Disease
about
Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to β-lactamsTargeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's diseaseN- and C-alkylation of seven-membered iminosugars generates potent glucocerebrosidase inhibitors and F508del-CFTR correctors.Pharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional chinese medicine.Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.New Directions in Gaucher Disease.Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease.Synthesis and evaluation of eight- and four-membered iminosugar analogues as inhibitors of testicular ceramide-specific glucosyltransferase, testicular β-glucosidase 2, and other glycosidases.Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.Structure-Activity Studies of N-Butyl-1-deoxynojirimycin (NB-DNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2.Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier.Conformational regulation of substituted azepanes through selective monofluorination.
P2860
Q27687260-10DD9F0C-EF50-4625-B9D6-AC04F34E5586Q28539839-778E1BE8-E334-4F38-B730-F1F19CEB6FF2Q35296367-7E9908E1-D689-41A7-BA9C-DCEB6F9C9738Q37556518-3258CF97-23B7-4C2B-B5CA-FAE857EA3F7FQ38797648-DCA982C8-E187-4079-AD73-6F154434899CQ38905996-F53AC80C-DE03-4BE9-854F-267872892767Q39162679-655DA234-A370-4AD2-B934-889352265947Q42322397-FF077472-D39D-4EF7-982F-1F314482BEC8Q42763507-30E3980F-8DEE-480F-8C27-A5879A4BA9F8Q47094962-686853E8-E35F-4774-8B57-A09EB76932AFQ51750678-8E900FC9-6105-41D3-94CA-E0554149B4D4Q53119099-905EAD12-3C67-466F-81EB-6D422CEF1900
P2860
Binding of 3,4,5,6-Tetrahydroxyazepanes to the Acid-β-glucosidase Active Site: Implications for Pharmacological Chaperone Design for Gaucher Disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@ast
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@en
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@nl
type
label
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@ast
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@en
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@nl
prefLabel
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@ast
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@en
Binding of 3,4,5,6-Tetrahydrox ...... one Design for Gaucher Disease
@nl
P2093
P2860
P356
P1433
P1476
Binding of 3,4,5,6-tetrahydrox ...... one design for Gaucher disease
@en
P2093
Neil P Grimster
Raquel L Lieberman
Susan D Orwig
Yun Lei Tan
Zhanqian Yu
P2860
P304
10647-10657
P356
10.1021/BI201619Z
P407
P577
2011-11-14T00:00:00Z